Loading...
•
Sep 30, 2021
Edwards Lifesciences Q3 2021 Earnings Report
Reported a 15 percent increase in sales, driven by growth in all product groups, despite the impact of the Delta variant.
Key Takeaways
Edwards Lifesciences reported a 15% increase in sales to $1.3 billion for the third quarter of 2021. The company's TAVR sales grew by 15%, and it made progress on five pivotal trials in TMTT. The company maintained its full-year 2021 sales guidance range and EPS guidance.
Sales grew 15 percent to $1.3 billion; underlying sales grew 14 percent.
TAVR sales grew 15 percent; underlying 14 percent.
U.S. TAVR sales grew 12 percent; OUS approximately 20 percent.
Continued progress on five pivotal trials in TMTT.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The company expects full year 2021 sales to fall within the previous guidance range of $5.2 to $5.4 billion and adjusted earnings per share guidance at the high end of $2.07 to $2.27. For the fourth quarter of 2021, the company projects sales to be between $1.30 and $1.38 billion, including TAVR between $850 and $910 million, and adjusted EPS of $0.53 to $0.59.
Positive Outlook
- Full year 2021 sales guidance range unchanged
- Full year EPS guidance remains unchanged
- Company projects sales to be between $1.30 and $1.38 billion for Q4 2021
- TAVR sales for Q4 2021 projected between $850 and $910 million
- Adjusted EPS of $0.53 to $0.59 for Q4 2021
Challenges Ahead
- Headwinds associated with the pandemic
- Some procedures were deferred in the third quarter due to the Delta variant
- TAVR sales were negatively impacted in the last two months of the third quarter due to the significant impact COVID had on hospital resources.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...